Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Enterprise Value: 2021-2025

Historic Enterprise Value for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $537.1 million.

  • Prime Medicine's Enterprise Value rose 82.75% to $537.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.0 million, marking a year-over-year increase of 160.12%. This contributed to the annual value of $195.5 million for FY2024, which is 73.79% down from last year.
  • As of Q3 2025, Prime Medicine's Enterprise Value stood at $537.1 million, which was up 137.71% from $226.0 million recorded in Q2 2025.
  • Prime Medicine's 5-year Enterprise Value high stood at $1.5 billion for Q4 2022, and its period low was -$253.7 million during Q4 2021.
  • For the 3-year period, Prime Medicine's Enterprise Value averaged around $559.7 million, with its median value being $537.1 million (2025).
  • As far as peak fluctuations go, Prime Medicine's Enterprise Value spiked by 1,426.10% in 2023, and later crashed by 81.01% in 2025.
  • Over the past 5 years, Prime Medicine's Enterprise Value (Quarterly) stood at -$253.7 million in 2021, then skyrocketed by 699.25% to $1.5 billion in 2022, then tumbled by 50.92% to $746.1 million in 2023, then slumped by 73.79% to $195.5 million in 2024, then surged by 82.75% to $537.1 million in 2025.
  • Its Enterprise Value was $537.1 million in Q3 2025, compared to $226.0 million in Q2 2025 and $120.7 million in Q1 2025.